US Stock Insider Trading | Savara disclosed 1 insider transaction on February 17

2026-02-20 23:16:20

On February 17, 2026, Savara (SVRA) disclosed one insider trading transaction. Director McCracken Joseph S purchased 1,807 shares on February 16, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Director	McCracken Joseph S	February 16, 2026	Buy	1807	1.76	3180.32
December 19, 2025	Director	RAMSAY DAVID A	December 19, 2025	Sell	20,000	6.06	121,200
December 16, 2025	Executive	Erickson Anne	December 14, 2025	Sell	63,000	6.92	435,600
December 16, 2025	Executive	Lowrance David L	December 14, 2025	Sell	63,000	6.92	435,600
December 16, 2025	Executive	McCabe Kathleen R.	December 14, 2025	Sell	39,400	6.92	273,048
December 16, 2025	Executive	Lutz Robert Matthew	December 14, 2025	Sell	68,000	6.92	469,600
December 16, 2025	Director	Pauls Matthew	December 14, 2025	Sell	195,700	6.92	1,354,204
December 4, 2025	Director	Elam Nevan C	December 2, 2025	Sell	1,473	5.81	8,558.13
December 4, 2025	Director	Elam Nevan C	December 2, 2025	Buy	5,860	1.46	8,556.60
December 4, 2025	Executive	Wasfi Yasmine	December 4, 2025	Sell	22,000	6.37	140,700

【Company Information】

Savara Inc., a Delaware corporation, is a biopharmaceutical company dedicated to developing treatments for serious or life-threatening diseases. The company has focused most of its resources on research and development (“R&D”) and acquiring its candidate products. The company has not yet gone public, sold any products, or generated significant revenue. In 2011, through its acquisition of SynthRx Ltd., the company acquired the membrane adhesion and sealant technology platform, including proprietary data related to Poloxamer and over twenty years of clinical, non-clinical, and manufacturing experience. The company is developing MST-188 using the Mast platform to treat diseases characterized by microcirculatory ischemia. In previous years, the company was developing Exelbine and ANX-514, both investigational oncology programs, but since early 2012, the company’s resources have been almost entirely focused on the development of MST-188.

The company was incorporated in December 1995 in Delaware.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes